AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
August 31, 2023 10:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference
May 09, 2023 10:38 ET
|
AI Therapeutics, Inc.
GUILFORD, Conn., May 09, 2023 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today Dr Antje Prasse...
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
December 19, 2022 07:00 ET
|
Revolution Medicines, Inc.
Findings Published in the Journal of Medicinal Chemistry Demonstrate Compound’s Exceptional Selectivity for mTORC1 over mTORC2 Tumor Regressions Observed During Combination Treatment with a Bi-Steric...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 09, 2022 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Moore Kuehn Encourages TGNA, MTOR, HMHC, and TEN Investors to Contact Law Firm
February 24, 2022 11:34 ET
|
Moore Kuehn
NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
MERITOR ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of MTOR and Encourages Investors to Contact the Firm
February 22, 2022 15:19 ET
|
Bragar Eagel & Squire
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 10, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
April 21, 2021 07:00 ET
|
Revolution Medicines, Inc.
First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development Newly Issued U.S. Patent Further Strengthens RMC-5552 IP Portfolio REDWOOD CITY, Calif., April 21, 2021 (GLOBE...
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 11, 2021 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit...
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 02, 2021 16:05 ET
|
Revolution Medicines, Inc.
Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to Support Targeted Combination...